ATH alterity therapeutics limited

New eye paper by Finkelstein et al

  1. 3,119 Posts.
    lightbulb Created with Sketch. 1160
    https://www.nature.com/articles/s41598-024-66284-7

    This is published in Nature, one of the best journals in the world.

    Here is the conclusion:

    Conclusions

    The current study is the first to examine HSI in a live mouse Parkinsonian retina. Hyperspectral imaging in two mouse PD models show a signature which is similar to an AD mouse model but completely distinct and opposite to that arising from healthy aging. We show preliminary evidence for an association of HSI with retinal levels of α-synuclein and iron. Furthermore, in aging, the integrity of the RNFL may influence HSI. Future studies which more comprehensively examine the biological drivers of PD and age-induced hyperspectral changes will pave the way for HSI as a non-invasive, scalable biomarker for neurodegenerative disease.


    I am waiting for this group to publish what ARH434 does to these changes. They seem to have many tools to study these changes.

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.1¢
Change
0.000(0.00%)
Mkt cap ! $119.6M
Open High Low Value Volume
1.1¢ 1.1¢ 1.0¢ $46.86K 4.283M

Buyers (Bids)

No. Vol. Price($)
64 25268416 1.0¢
 

Sellers (Offers)

Price($) Vol. No.
1.1¢ 18128695 9
View Market Depth
Last trade - 16.10pm 19/09/2025 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.